Updates from Recursion
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration (Partnership · October 15, 2026)
Sanofi exercised an option to advance a potential first-in-class small molecule candidate from its collaboration with Recursion. The drug is designed to target inflammatory diseases and is expected… - Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone (Project update · October 15, 2026)
Recursion shared positive Phase 2 results for REC-4881, an investigational treatment for familial adenomatous polyposis. The data showed significant reductions in polyp burden across the…